Canada Pension Plan Investment Board Mirati Therapeutics, Inc. Transaction History

Canada Pension Plan Investment Board

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$36.54 - $54.26 $519,452 - $771,360	14,216 Added 682.15%	16,300 $606,000
Q4 2022 Feb 14, 2023	BUY	$41.27 - $98.62 $86,006 - $205,524	2,084 New	2,084 $94,000
Q1 2022 May 13, 2022	SELL	$75.82 - $150.97 $3.72 Million - $7.4 Million	-49,000 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$132.01 - $190.29 $6.47 Million - $9.32 Million	49,000 New	49,000 $7.19 Million
Q3 2021 Nov 15, 2021	SELL	$132.13 - $177.45 $32,503 - $43,652	-246 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$144.0 - $179.73 $278,928 - $348,137	-1,937 Reduced 88.73%	246 $40,000
Q1 2021 May 17, 2021	BUY	$158.92 - $221.61 $302,424 - $421,723	1,903 Added 679.64%	2,183 $374,000
Q4 2020 Feb 17, 2021	BUY	$162.05 - $240.27 $45,374 - $67,275	280 New	280 $61,000
Q2 2020 Aug 14, 2020	SELL	$72.01 - $120.39 $159,214 - $266,182	-2,211 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$69.78 - $116.21 $152,190 - $253,454	2,181 Added 7270.0%	2,211 $170,000
Q4 2019 Feb 14, 2020	BUY	$70.76 - $128.86 $2,122 - $3,865	30 New	30 $4,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Canada Pension Plan Investment Board, based on Form 13F filings with the SEC.

Stay updated on Canada Pension Plan Investment Board with notifications on news.